I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat
Cancer drug maker has been in a wide range of market-moving headlines lately, though its stock still trades near an all-time low Key Takeaways: I-Mab was placed on a list…
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Innovent Bio hopes for plus-sized profits from obesity drug
1801.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
-
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
Akeso marks profit milestone with swift rights issue
9926.HK
Discover hidden China stock gems in our weekly newsletter